Abstract:In women with reproductive potential, ovarian dysfunction caused by chemotherapy for breast cancer has far-reaching effects. Ovarian insufficiency can manifest as amenorrhea, menstrual disorders, hot flashes and night sweats, impaired fertility in the short term, and increased cardiovascular risk, reduced bone density, cognitive impairment in the long term. The occurrence of ovarian insufficiency due to chemotherapy is closely related to the type of drug, the number of chemotherapy sessions, the dose of chemotherapy, and the age of the patient. There are many drugs for protecting ovarian function, but in clinical practice, gonadotropin-releasing hormone analogues (GnRHa) are still the mainstay. Other ovarian protection drugs generally lack clinical trial data, and their safety and impact on chemotherapy efficacy need further research.